Genetic determinants of warfarin dosing in the Han-Chinese population (Q43230870)

16 November 2017

Genetic determinants of warfarin dosing in the Han-Chinese population (English)

1 reference

16 November 2017

1 reference

11

Yuan-Tsong Chen

1 reference

16 November 2017

M T Michael Lee

1

1 reference

16 November 2017

Chien-Hsiun Chen

2

1 reference

16 November 2017

Ching-Heng Chou

3

1 reference

16 November 2017

Liang-Suei Lu

4

1 reference

16 November 2017

Hui-Ping Chuang

5

1 reference

16 November 2017

Ying-Ting Chen

6

1 reference

16 November 2017

Amir N Saleem

7

1 reference

16 November 2017

Ming-Shien Wen

8

1 reference

16 November 2017

Jin-Jer Chen

9

1 reference

16 November 2017

Jer-Yuarn Wu

10

1 reference

16 November 2017

language of work or name

1 reference

1 December 2009

1 reference

16 November 2017

1 reference

16 November 2017

10

1 reference

16 November 2017

12

1 reference

16 November 2017

1905-1913

1 reference

Antithrombotic therapy in deep vein thrombosis and pulmonary embolism

16 November 2017

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Interindividual variability in sensitivity to warfarin--Nature or nurture?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Bleeding Complications to Long-Term Oral Anticoagulant Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

CYP2C9 allelic variants: ethnic distribution and functional significance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

A novel fluorescence assay to study propeptide interaction with gamma-glutamyl carboxylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Association of warfarin dose with genes involved in its action and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

CYP4F2 genetic variant alters required warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

PrimerZ: streamlined primer design for promoters, exons and human SNPs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

Warfarin and the Inhibition of Vitamin K Activity by an Oxide Metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.106

21 January 2018

Identifiers

DOI

10.2217/PGS.09.106

1 reference

16 November 2017

1 reference